Life Sciences: An Undervalued Megatrend?

🧬 *Invest in top-performing biotech stocks* _Install FREE app_ : https://optothemes.onelink.me/BZDG/ti2lb2fd Over the past 25 years, the Nasdaq Biotechnology Index has outperformed the *S&P500 by 467%.* This growth, fueled by a tripling in FDA drug approvals since 2002, coincides with the UN's prediction that the *over-60 population will double by 2050,* driving healthcare spending to unprecedented levels. Today, we delve into the *challenges and opportunities in the biotech sector* with Yuri Khodjamirian, CIO of Tema ETFs. We explore how investors can navigate the sector's regulatory, scientific, and funding risks to capitalise on this *demographic shift and historically low valuations.* Prior to Tema ETFs, Yuri spent over a decade at Majedie Asset Management managing the firm’s UK and global portfolios. Enjoy! 🎯 Key Takeaways: 00:00 Start 01:37 Life Sciences Growth 05:46 Personalised Medicine 06:32 How US Elections Outcome Could Impact Biotech 8:49 AI's Impact on Biotech 15:40 Managing Risks in Biotech Investments 20:08 Ethical Considerations 26:14 How to Invest in Biotech 31:40 Tema's Investment Process 34:21 Funds Strategy & Performance 40:21 Innovative Cancer Treatments: ADCs & Radiotherapy 📲 *Invest in innovation with OPTO* _Install FREE app_ : https://optothemes.onelink.me/BZDG/ti2lb2fd X: https://twitter.com/OptoThemes Instagram: https://www.instagram.com/opto.themes?igsh=MXhwenU4dTk4aDBqMw%3D%3D&utm_source=qr LinkedIn: https://www.linkedin.com/in/opto-invest-in-innovation-308416193/ Facebook: https://www.facebook.com/OptoThemes #biotech #lifesciences #biotechstocks #biotechnology #investininnovation #temaetfs Disclaimer: https://optothemes.com/disclosures-and-legal-documentation